Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial

William L Baker1, 3, *, Jeffrey Kluger2, 4, Craig I Coleman1, 3, C Michael White1, 3
1 University of Connecticut, Schools of Pharmacy, Hartford CT, USA
2 University of Connecticut, Schools of Medicine, Hhartford CT, USA
3 Storrs and Farmington, Hartford Hospital, Division of Pharmacy, Hartford CT, USA
4 Storrs and Farmington, Hartford Hospital, Division of Cardiology, Hartford CT, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1172
Abstract HTML Views: 539
PDF Downloads: 269
Total Views/Downloads: 1980
Unique Statistics:

Full-Text HTML Views: 482
Abstract HTML Views: 325
PDF Downloads: 206
Total Views/Downloads: 1013

Creative Commons License
© Baker et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( 3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the University of Connecticut, Schools of Pharmacy, Hartford CT, USA; Tel: 860-972-7918; E-mails:,



We evaluated the antiarrhythmic efficacy and quality of life (QoL) impact of oral magnesium Llactate on patients with an implantable cardioverter defibrillator (ICD).


This prospective, double-blind, placebo-controlled trial randomized 70 patients with an ICD to receive oral magnesium L-lactate 3 tablets twice daily (504mg elemental magnesium daily) or matching placebo for 12 months. Patients were seen at baseline, 12, 24, 36, and 52 weeks. The primary endpoints were the cumulative occurrence of ICD therapy [either shock or anti-tachycardia pacing (ATP)] or QoL between the groups.


Among the 70 randomized patients with a mean ± SD follow-up of 6.4 ± 4.1 months, 10 patients in the placebo group and 8 in the magnesium group experienced either ICD shock or ATP [HR 0.84, 95% CI 0.33 to 2.12; p=0.706]. Without significant arrhythmia suppression, only minimal effects on QoL were seen. Eighty six percent of all patients had serum intracellular magnesium deficiency.


In our underpowered trial, patients with ICDs had intracellular magnesium deficiency but oral magnesium Llactate only nonsignificantly reduced the occurrence of ICD therapies and had little impact on HrQoL.

Keywords: Magnesium, implantable cardioverter defibrillator, arrhythmia, quality of life.